Metsera, Inc. (NASDAQ:MTSR – Get Free Report) reached a new 52-week high during trading on Tuesday . The stock traded as high as $32.33 and last traded at $32.19, with a volume of 70254 shares. The stock had previously closed at $30.58.
Metsera Price Performance
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
- Five stocks we like better than Metsera
- P/E Ratio Calculation: How to Assess Stocks
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- What is the Nasdaq? Complete Overview with History
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo-1200x675.jpg?v=20240515130629&h=45&w=95&zc=2){kind=logo}
